SMU Medical Journal

Ganeva Silviya ¹, Todorova Katya ¹, Lukanov Tsvetan ², Rayanova Ginka ¹, Blajeva Svetla ², Tsvyatkovska Tsvetomira ¹

Affiliations
1 Medical University Pleven, UMHAT “D-r G. Stranski”, Clinic of Endocrinology and Metabolic Diseases, BG
2 Medical University Pleven, UMHAT “D-r G. Stranski”, Medico-Diagnostic Laboratory of Immunology, BG

Abstract

A considerable suggestion exists between the leukocyte count, lymphocyte (lymph) dysfunction and the possibility of developing DMt2. Aim of the study was to investigate the CD19 +expression of B- lymph in peripheral blood in patients with metabolic syndrome (MS) without and with Diabetes mellitus type 2 (DMt2). A prospective, one-year, comparative, observational study was performed. In 26 MS patients without DMt2 (n₁=26) and 69 with DMt2 (n₂=69) were measured and compared the levels of leucocytes and CD19+ B- lymph subtypes in peripheral blood by flow-cytometric analysis. The leucocytes count is in normal range in both groups with MS. DMt2 patients have a higher leucocytes count (n₁=6.93±1.92.10⁹ vs n₂=7.27±1.85.10⁹; р= 0,04) in the referent range. The percentage of the common lymphocytes population was also higher among n1 patients compared to n2, but without significant difference in their absolute count [(n₁=38,26%±7,43% vs. n₂=33,42%±7,08%) and (n₁=2.58±0.8.10⁹ vs. n₁=3,45±0,67.10⁹)]. The percentage ratio and absolute count of СD19+ B- lymphocytes subtypes in patients from both groups was lower than referent values, but without significant difference between the two groups.The levels of СD19+B-lymphocytes in peripheral blood are lower in patients with MS irrespective of the level of glycaemia.

Keywords

Metabolic Syndrome, B-Lymphocytes, Type 2 Diabetes Mellitus Risk, Flow-Cytometry.

Full Text

   

Rayanova Ginka ¹, Ganeva Silviya ¹, Todorova Кatya ¹, Lukanov Tsvetan ², Blajeva Svetla ²

Affiliations
1 Medical University Pleven, UMHAT “D-r Georgi Stranski”, Clinic of Endocrinology and Metabolic Diseases, Medico-Diagnostic Laboratory of Immunology, BG
2 Medical University Pleven, UMHAT “D-r Georgi Stranski”, Medico-Diagnostic Laboratory of Immunology, BG

Abstract

It has been recently proven, that the adipose tissue is not just a passive energy depot, but rather active endocrine organ – adipocytes are expressing on their surface multiple receptors and are releasing adipokines, hormones, cytokines, growth factors. Aim of the present study was to examine the serum levels of adipokines – adiponectin and resistin in patients with metabolic syndrome (MS) and newly diagnosed diabetes mellitus type 2 (NDDMt2). A prospective, comparative, observational study was performed. In 45 subjects with MS and NDDMt2 (n₁=45) and 35 clinical health subjects (n₂=35) were measured and compared the serum levels of adipokines – adiponectin and resistin. Two homoeostasis models assessment of insulin resistance (HOMA-IR) and of β-cell function (HOMA-%В) were calculated. A significantly lower level of adiponectin was detected in patients with MS and NDDMt2 in comparison whit the control group (n₁=0.97±0.47 vs. n₂=1.96±0.73 μg/ml; p=0.005). A significantly higher level of resistin was found in patients with MS and NDDMt2 in comparison whit controls (n₁=1.85±0.70 vs. n₂=0.71±0.31 ng/ml; p=0.025). We have found negative correlations between concentration of adiponectin and serum levels of resistin, BMI and waist circumference in MS and NDDMt2 patients. The resistin was positively correlated with BMI and waist circumference, and was negatively correlated with HDL-cholesterol in MS and NDDMt2 patients.Patients with MS and NDDMt2 exhibited significantly changes in levels of adiponectin and resistin. Indicated adipokines may have predictive value of progression from normal to pathological carbohydrate metabolism.

Keywords

Metabolic Syndrome, Newly Diagnosed Diabetes Mellitus Type 2, Adiponectin, Resistin.

Full Text